---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-107824"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-09-18T23:59:59+00:00"
generated_at: "2026-05-31T03:57:32.677657+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Akari updates Peak Bio merger conditions, CEO compensation revised, pipeline prioritization

## Summary
- Merger with Peak Bio conditions include Peak Bio net cash > -$13.5M and PIPE net proceeds ≥ $10M; expected closing Q4 2024.
- Post-merger combined entity to focus on Peak Bio's ADC platform and Akari's PAS-nomacopan GA program; HSCT-TMA suspended.
- Interim CEO Samir Patel's monthly $50k compensation changed from shares to NQSOs with 2x ADS multiplier.
- PAS-nomacopan IND filing for geographic atrophy expected in 2025; preclinical data suggests 3-month+ intravitreal dosing.

## SEC filing metadata
- accession: 0000950170-24-107824
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-09-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017024107824/0000950170-24-107824-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017024107824/aktx-20240913.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-107824
- JSON: https://secwatch.observer/filing/0000950170-24-107824.json
- Plain text: https://secwatch.observer/filing/0000950170-24-107824.txt

## Key facts
- Executive change
  Robert Bazemore was appointed as director at Akari Therapeutics Plc.
  - Action: appointed
  - Role: director
  source text: the appointment of Robert Bazemore to serve as a director of the Board, effective as of September 17, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1541157/000095017024107824/0000950170-24-107824-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.